For how we live.
Cleared on 30 October under accelerated approval, the Inovio therapy is the first plasmid-DNA immunotherapy for this rare airway disease. In its trial, 7 of 26 adults needed no surgery in the following year.
The FDA logged a Class I recall of Ventec's VOCSN, V+Pro, VC and V*Home ventilators on 28 October, citing an internal cable connector that can detach, rebooting the device and interrupting breathing support.
The PLUSS trial put a steroid directly into the lungs of 1,059 infants born before 28 weeks. Survival free of chronic lung disease barely differed from surfactant alone.
A randomised trial at eight South Korean hospitals found pulse methylprednisolone no better than a non-pulse regimen for surviving an acute exacerbation of idiopathic pulmonary fibrosis.
Brensocatib blocks an enzyme that arms neutrophils rather than killing bacteria. In a 1,721-patient trial it cut yearly flare-ups by about a fifth — a modest effect in a disease with nothing else approved.